Applied DNA Sciences, Inc. Logo

Applied DNA Sciences, Inc.

APDN

(1.0)
Stock Price

0,19 USD

-52.65% ROA

-136.86% ROE

-0.2x PER

Market Cap.

3.799.449,00 USD

7.01% DER

0% Yield

-216.77% NPM

Applied DNA Sciences, Inc. Stock Analysis

Applied DNA Sciences, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Applied DNA Sciences, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (19%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 PBV

The stock's PBV ratio (1.48x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

3 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

4 ROE

Negative ROE (-72.49%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

5 ROA

The stock's ROA (-45.14%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

8 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

Investors should note the absence of dividends from the company in the last three years, indicating potential financial challenges.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (-1) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Applied DNA Sciences, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Applied DNA Sciences, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Sell
4 Stoch RSI Sell

Applied DNA Sciences, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Applied DNA Sciences, Inc. Revenue
Year Revenue Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 18.900 100%
2007 121.920 84.5%
2008 873.010 86.03%
2009 295.162 -195.77%
2010 519.844 43.22%
2011 968.848 46.34%
2012 1.854.694 47.76%
2013 2.036.222 8.91%
2014 2.721.224 25.17%
2015 9.008.499 69.79%
2016 4.186.427 -115.18%
2017 4.751.260 11.89%
2018 3.903.343 -21.72%
2019 5.389.089 27.57%
2020 1.931.497 -179.01%
2021 9.027.738 78.6%
2022 18.168.677 50.31%
2023 13.367.443 -35.92%
2024 3.190.076 -319.03%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Applied DNA Sciences, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 638.873 100%
2006 153.191 -317.04%
2007 110.845 -38.2%
2008 145.832 23.99%
2009 135.405 -7.7%
2010 75.961 -78.26%
2011 268.876 71.75%
2012 432.669 37.86%
2013 692.480 37.52%
2014 1.300.750 46.76%
2015 1.635.381 20.46%
2016 3.693.810 55.73%
2017 2.282.362 -61.84%
2018 2.751.578 17.05%
2019 2.967.278 7.27%
2020 3.321.763 10.67%
2021 3.765.440 11.78%
2022 3.926.043 4.09%
2023 3.735.078 -5.11%
2024 3.115.472 -19.89%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Applied DNA Sciences, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 17.580.098 100%
2005 42.662.152 58.79%
2006 8.530.354 -400.12%
2007 12.096.444 29.48%
2008 4.277.013 -182.82%
2009 6.576.434 34.96%
2010 7.126.091 7.71%
2011 8.388.873 15.05%
2012 7.615.734 -10.15%
2013 11.198.505 31.99%
2014 13.249.753 15.48%
2015 14.736.451 10.09%
2016 11.239.397 -31.11%
2017 13.324.503 15.65%
2018 11.043.463 -20.66%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Applied DNA Sciences, Inc. EBITDA
Year EBITDA Growth
1998 -634
1999 -1.582 59.92%
2000 -3.354 52.83%
2001 -5.720 41.36%
2002 -8.582 33.35%
2003 -3.493.363 99.75%
2004 -15.956.483 78.11%
2005 -34.476.141 53.72%
2006 -24.437.106 -41.08%
2007 -10.688.407 -128.63%
2008 -3.721.166 -187.23%
2009 -6.477.915 42.56%
2010 -6.745.137 3.96%
2011 -7.688.901 12.27%
2012 -6.193.709 -24.14%
2013 -2.346.617 -163.94%
2014 -10.921.274 78.51%
2015 -3.387.951 -222.36%
2016 -11.493.362 70.52%
2017 -11.932.837 3.68%
2018 -11.135.517 -7.16%
2019 -7.473.448 -49%
2020 -12.627.344 40.82%
2021 -9.691.184 -30.3%
2022 -21.377.684 54.67%
2023 -10.445.441 -104.66%
2024 -12.850.120 18.71%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Applied DNA Sciences, Inc. Gross Profit
Year Gross Profit Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 3.261 100%
2007 98.847 96.7%
2008 701.678 85.91%
2009 233.924 -199.96%
2010 456.915 48.8%
2011 968.848 52.84%
2012 1.854.694 47.76%
2013 2.036.222 8.91%
2014 2.721.224 25.17%
2015 8.624.230 68.45%
2016 3.439.845 -150.72%
2017 3.674.028 6.37%
2018 2.696.529 -36.25%
2019 4.511.476 40.23%
2020 1.210.597 -272.67%
2021 4.928.350 75.44%
2022 5.053.640 2.48%
2023 5.533.432 8.67%
2024 444.276 -1145.49%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Applied DNA Sciences, Inc. Net Profit
Year Net Profit Growth
1998 -634
1999 -1.582 59.92%
2000 -3.354 52.83%
2001 -5.720 41.36%
2002 -8.582 33.35%
2003 -3.445.164 99.75%
2004 -19.358.259 82.2%
2005 -52.610.380 63.2%
2006 -2.410.237 -2082.79%
2007 -13.304.833 81.88%
2008 -6.802.898 -95.58%
2009 3.944.578 272.46%
2010 -7.909.600 149.87%
2011 -10.515.124 24.78%
2012 -7.150.712 -47.05%
2013 -17.686.472 59.57%
2014 -13.066.661 -35.36%
2015 -11.881.137 -9.98%
2016 -12.175.979 2.42%
2017 -12.855.767 5.29%
2018 -11.692.928 -9.94%
2019 -8.632.446 -35.45%
2020 -12.764.974 32.37%
2021 -16.029.225 20.36%
2022 -8.377.996 -91.33%
2023 -9.947.059 15.77%
2024 7.519.184 232.29%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Applied DNA Sciences, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1998 -8
1999 -26 73.08%
2000 -56 52.73%
2001 -95 42.11%
2002 -7 -1257.14%
2003 -638 98.9%
2004 -2.232 71.4%
2005 -1.975 -12.96%
2006 -49 -3930.61%
2007 -236 79.24%
2008 -85 -177.65%
2009 48 277.08%
2010 -63 176.19%
2011 -67 4.55%
2012 -30 -127.59%
2013 -1.206 97.6%
2014 -773 -56.02%
2015 -502 -54.29%
2016 -411 -21.9%
2017 -390 -5.66%
2018 -317 -22.71%
2019 -187 -69.52%
2020 -65 -187.69%
2021 -46 -41.3%
2022 -19 -155.56%
2023 -15 -20%
2024 2 1600%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Applied DNA Sciences, Inc. Free Cashflow
Year Free Cashflow Growth
1998 0
1999 -3.000 100%
2000 -4.622 35.09%
2001 -400 -1055.5%
2002 -9.865 95.95%
2003 -491.509 97.99%
2004 -3.098.226 84.14%
2005 -9.116.045 66.01%
2006 -3.048.386 -199.04%
2007 -2.262.619 -34.73%
2008 -2.948.780 23.27%
2009 -2.468.598 -19.45%
2010 -2.455.189 -0.55%
2011 -3.850.824 36.24%
2012 -4.123.512 6.61%
2013 -8.506.901 51.53%
2014 -8.742.329 2.69%
2015 -7.604.414 -14.96%
2016 -10.681.989 28.81%
2017 -7.624.620 -40.1%
2018 -7.183.217 -6.14%
2019 -6.929.210 -3.67%
2020 -12.206.757 43.23%
2021 -15.936.650 23.4%
2022 -9.466.259 -68.35%
2023 -6.296.125 -50.35%
2024 -3.516.486 -79.05%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Applied DNA Sciences, Inc. Operating Cashflow
Year Operating Cashflow Growth
1998 0
1999 -3.000 100%
2000 -4.622 35.09%
2001 -400 -1055.5%
2002 -9.865 95.95%
2003 -491.509 97.99%
2004 -3.068.719 83.98%
2005 -9.116.045 66.34%
2006 -2.883.815 -216.11%
2007 -2.251.580 -28.08%
2008 -2.926.280 23.06%
2009 -2.468.598 -18.54%
2010 -2.455.189 -0.55%
2011 -3.761.716 34.73%
2012 -3.960.679 5.02%
2013 -7.870.353 49.68%
2014 -8.512.738 7.55%
2015 -6.965.846 -22.21%
2016 -9.896.727 29.61%
2017 -7.479.184 -32.32%
2018 -6.917.209 -8.12%
2019 -6.861.772 -0.81%
2020 -11.143.059 38.42%
2021 -13.387.955 16.77%
2022 -8.976.706 -49.14%
2023 -6.217.677 -44.37%
2024 -3.494.660 -77.92%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Applied DNA Sciences, Inc. Capital Expenditure
Year Capital Expenditure Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 29.507 100%
2005 0 0%
2006 164.571 100%
2007 11.039 -1390.81%
2008 22.500 50.94%
2009 0 0%
2010 0 0%
2011 89.108 100%
2012 162.833 45.28%
2013 636.548 74.42%
2014 229.591 -177.25%
2015 638.568 64.05%
2016 785.262 18.68%
2017 145.436 -439.94%
2018 266.008 45.33%
2019 67.438 -294.45%
2020 1.063.698 93.66%
2021 2.548.695 58.26%
2022 489.553 -420.62%
2023 78.448 -524.05%
2024 21.826 -259.42%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Applied DNA Sciences, Inc. Equity
Year Equity Growth
1998 -3.649
1999 -5.231 30.24%
2000 -963 -443.2%
2001 -1.283 24.94%
2002 135 1050.37%
2003 -577.427 100.02%
2004 -4.706.508 87.73%
2005 6.586.623 171.46%
2006 -9.586.197 168.71%
2007 -11.944.512 19.74%
2008 -14.037.568 14.91%
2009 -1.746.832 -703.6%
2010 -1.598.030 -9.31%
2011 -995.385 -60.54%
2012 756.925 231.5%
2013 4.616.037 83.6%
2014 -1.468.476 414.34%
2015 12.566.856 111.69%
2016 10.365.402 -21.24%
2017 6.858.080 -51.14%
2018 754.503 -808.95%
2019 -848.499 188.92%
2020 5.709.506 114.86%
2021 11.112.946 48.62%
2022 12.908.939 13.91%
2023 4.872.412 -164.94%
2024 12.234.455 60.17%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Applied DNA Sciences, Inc. Assets
Year Assets Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 135 100%
2003 207.361 99.93%
2004 81.647 -153.97%
2005 9.182.520 99.11%
2006 4.676.830 -96.34%
2007 2.411.788 -93.92%
2008 1.846.877 -30.59%
2009 1.507.070 -22.55%
2010 1.413.314 -6.63%
2011 3.503.556 59.66%
2012 1.348.934 -159.73%
2013 8.374.966 83.89%
2014 3.506.057 -138.87%
2015 15.554.312 77.46%
2016 15.565.831 0.07%
2017 8.153.948 -90.9%
2018 5.633.733 -44.73%
2019 3.564.735 -58.04%
2020 11.341.179 68.57%
2021 14.416.756 21.33%
2022 22.265.114 35.25%
2023 13.651.577 -63.1%
2024 16.690.090 18.21%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Applied DNA Sciences, Inc. Liabilities
Year Liabilities Growth
1998 3.649
1999 5.231 30.24%
2000 963 -443.2%
2001 1.283 24.94%
2002 0 0%
2003 784.788 100%
2004 4.788.155 83.61%
2005 2.595.897 -84.45%
2006 14.263.027 81.8%
2007 14.356.300 0.65%
2008 15.884.445 9.62%
2009 3.253.902 -388.17%
2010 3.011.344 -8.05%
2011 4.498.941 33.07%
2012 592.009 -659.94%
2013 3.758.929 84.25%
2014 4.974.533 24.44%
2015 2.987.456 -66.51%
2016 5.200.429 42.55%
2017 1.295.868 -301.31%
2018 4.879.230 73.44%
2019 4.413.234 -10.56%
2020 5.631.673 21.64%
2021 3.303.810 -70.46%
2022 9.356.175 64.69%
2023 8.779.165 -6.57%
2024 4.455.636 -97.04%

Applied DNA Sciences, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.85
Net Income per Share
-1.83
Price to Earning Ratio
-0.2x
Price To Sales Ratio
1.12x
POCF Ratio
-0.11
PFCF Ratio
-0.29
Price to Book Ratio
0.12
EV to Sales
-1.7
EV Over EBITDA
0.34
EV to Operating CashFlow
0.44
EV to FreeCashFlow
0.44
Earnings Yield
-4.97
FreeCashFlow Yield
-3.44
Market Cap
0,00 Bil.
Enterprise Value
-0,01 Bil.
Graham Number
11.29
Graham NetNet
1.65

Income Statement Metrics

Net Income per Share
-1.83
Income Quality
1.79
ROE
-1.37
Return On Assets
-0.44
Return On Capital Employed
-1.09
Net Income per EBT
1
EBT Per Ebit
0.5
Ebit per Revenue
-4.39
Effective Tax Rate
-0.02

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.99
Stock Based Compensation to Revenue
0.26
Gross Profit Margin
0.16
Operating Profit Margin
-4.39
Pretax Profit Margin
-2.17
Net Profit Margin
-2.17

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
-0.01
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-3.27
Free CashFlow per Share
-3.25
Capex to Operating CashFlow
-0.01
Capex to Revenue
0.02
Capex to Depreciation
0.08
Return on Invested Capital
-1.15
Return on Tangible Assets
-0.53
Days Sales Outstanding
55.2
Days Payables Outstanding
203.55
Days of Inventory on Hand
59.81
Receivables Turnover
6.61
Payables Turnover
1.79
Inventory Turnover
6.1
Capex per Share
0.02

Balance Sheet

Cash per Share
2,60
Book Value per Share
3,05
Tangible Book Value per Share
2.38
Shareholders Equity per Share
3.09
Interest Debt per Share
-0.28
Debt to Equity
0.07
Debt to Assets
0.05
Net Debt to EBITDA
0.56
Current Ratio
3.91
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,01 Bil.
Invested Capital
12914439
Working Capital
0,01 Bil.
Intangibles to Total Assets
0.16
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
402907
Debt to Market Cap
0.23

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Applied DNA Sciences, Inc. Dividends
Year Dividends Growth

Applied DNA Sciences, Inc. Profile

About Applied DNA Sciences, Inc.

Applied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes. The company's supply chain security and product authentication solutions include SigNature molecular tags that provide forensic power and protection for various applications used to fortify brand protection efforts and strengthen supply chain security, as well as mark, track, and convict criminals; SigNify IF portable DNA readers and SigNify consumable reagent test kits that provide real-time authentication of molecular tags in the field; and CertainT, which indicates the use of tagging, testing, and tracking platforms and solutions enabling manufacturers, brands, and trade organizations to convey proof of their product claims. It also manufactures and sells COVID-19 PCR-based molecular diagnostic test kit under the LineaTM COVID-19 Assay Kit trademark; and COVID-19 diagnostic test kit to prevent virus spread within a community, school, or workplace under the safeCircle trademark. In addition, the company provides preclinical contract research and manufacturing services for the nucleic acid-based therapeutic markets; and contract research services to RNA based drug and biologic customers for preclinical studies. Further, it develops an invasive circulating tumor cell capture and identification technology that uses a patented functional assay to capture live invasive circulating tumor cell and associated lymphocytes. The company operates in the United States, Europe, Asia, and internationally. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.

CEO
Dr. James A. Hayward Ph.D., Sc
Employee
52
Address
50 Health Sciences Drive
Stony Brook, 11790

Applied DNA Sciences, Inc. Executives & BODs

Applied DNA Sciences, Inc. Executives & BODs
# Name Age
1 Ms. Beth M. Jantzen CPA
Chief Financial Officer
70
2 Ms. Judith Murrah
Chief Operating Officer, Chief Information Officer & Secretary
70
3 Mr. Clay Shorrock Esq., J.D.
Chief Legal Officer & Executive Director of Business Development
70
4 Mr. Sanjay M. Hurry
Executive Director of Investor Relations & Corporate Communications
70
5 Dr. James A. Hayward Ph.D., Sc.D.
Chairman, President & Chief Executive Officer
70

Applied DNA Sciences, Inc. Competitors